“Partnering with Meridian will bring additional resources and expertise to Raleigh Neurology that will enable us to continue offering valuable clinical trials to our patient communities.” — Kenneth Carnes, MD, PhD

RALEIGH, N.C. (PRWEB)
May 03, 2022

Meridian Clinical Research, a leading multi-specialty investigative research site network has partnered with Raleigh Neurology Associates, PA, a premier provider of neurological care that has served the Triangle area for almost 40 years. The research site will be located within the Raleigh Neurology clinic at 1520 Sunday Drive, Suite 301, Raleigh, NC 27607.

Raleigh Neurology’s distinguished physicians — including Kenneth Carnes, MD, PhD, A. Thomas Perkins IV, MD, PhD, Bradley Robottom, MD, and John Scagnelli, MD — will serve as principal investigators, overseeing clinical trials for investigational products intended to help treat disorders of the nervous system, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, migraines, and other neurological conditions.

Nicole Osborn, Founder and CEO of Meridian, said the partnership will leverage Raleigh Neurology’s existing clinical research experience. “These neurologists have exceptional research experience,” said Osborn. “As Sponsors and CROs continue to design more specialized trials for highly-targeted therapies, the skill and niche experience of investigators and clinical staff is becoming a greater asset. We look forward to supporting a broader range of both specialty and high-volume clinical trials with Raleigh Neurology.”

“Partnering with Meridian will bring additional resources and expertise to Raleigh Neurology that will enable us to continue offering valuable clinical trials to our patient communities,” Dr. Carnes noted. “Clinical trials often provide the environment that fosters the scientific breakthroughs required to create new therapies. These trials make it possible for researchers to collect safety and efficacy data on potential therapies and offer valuable treatment options to patients with neurodegenerative diseases.”

Meridian now has 32 sites nationwide. Since opening in Omaha in 1999, Meridian has enrolled more than 80,000 patients in 3,400 clinical trials. In 2020, the company began conducting COVID-19 vaccine clinical trials for the vaccines that have received FDA approval.

If you’re interested in joining a clinical trial at Meridian or want to sign up to learn about upcoming studies, visit mcrmed.com/find-study. For more information about careers at Meridian and current openings in Raleigh, visit mcrmed.com/careers.

ABOUT MERIDIAN CLINICAL RESEARCH

Meridian Clinical Research, partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, and diagnostics that could improve human health and wellbeing. Founded in 1999, Meridian is a multi-specialty site network headquartered at its dedicated research center in Omaha, NE, and conducts Phase 1-4 studies at investigative sites nationwide. Meridian supports research across numerous therapeutic areas and excels in high-volume vaccine trials. For more information, visit mcrmed.com.

Share article on social media or email: